This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
March 01, 2021
Nordic Nanovector ASA – Notice of extraordinary general meeting
March 01, 2021
Oncorena Receives Approval of First in Patient Trial with Orellanine as a Potential Breakthrough Therapy in Metastatic Renal Cancer Patients
February 27, 2021
BONESUPPORT’S FDA NOTIFICATION: APPROVAL ON DENOVO PATHWAY FOR CERAMENT G WILL REQUIRE ADDITIONAL DATA AND CLARIFICATIONS
February 26, 2021
FDA approves Oncopeptides’ PEPAXTO® ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma
February 26, 2021
Year-end report 2020
February 25, 2021
Strongbridge Biopharma plc to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call on March 3, 2021
February 23, 2021
Nordic Nanovector ASA – Key information regarding potential repair offering
February 23, 2021
Nordic Nanovector – Private placement successfully completed
February 23, 2021
Nordic Nanovector launches a private placement of new shares
February 23, 2021
Continued survival benefit in Targovax’s ONCOS-102 trial in mesothelioma at the 21-month follow-up